Ngā hua rapu - Tebbutt, Niall C

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature mā Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature mā Chan, David L., Pavlakis, Nick, Shapiro, Jeremy, Price, Timothy J., Karapetis, Christos S., Tebbutt, Niall C., Segelov, Eva

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials mā Hurwitz, Herbert I., Tebbutt, Niall C., Kabbinavar, Fairooz, Giantonio, Bruce J., Guan, Zhong-Zhen, Mitchell, Lada, Waterkamp, Daniel, Tabernero, Josep

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus mā Davey, Rachel A, Tebbutt, Niall C, Favaloro, Jenny M, O'Neal, David N, Rae, Derek, Zajac, Jeffrey D, Best, James D

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction mā Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines mā Yeung, Yvonne, Lau, David K., Chionh, Fiona, Tran, Hoanh, Tse, Janson W. T., Weickhardt, Andrew J., Nikfarjam, Mehrdad, Scott, Andrew M., Tebbutt, Niall C., Mariadason, John M.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study mā Lau, David K., Tay, Rebecca Y., Yeung, Yvonne H., Chionh, Fiona, Mooi, Jennifer, Murone, Carmel, Skrinos, Effie, Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* mā Price, Timothy J, Hardingham, Jennifer E, Lee, Chee K, Townsend, Amanda R, Wrin, Joseph W, Wilson, Kate, Weickhardt, Andrew, Simes, Robert J, Murone, Carmel, Tebbutt, Niall C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT] mā Clarke, Stephen John, Burge, Matthew, Feeney, Kynan, Gibbs, Peter, Jones, Kristian, Marx, Gavin, Molloy, Mark P., Price, Timothy, Reece, William H. H., Segelov, Eva, Tebbutt, Niall C.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial mā Klein, Oliver, Kee, Damien, Nagrial, Adnan, Markman, Ben, Underhill, Craig, Michael, Michael, Jackett, Louise, Lum, Caroline, Behren, Andreas, Palmer, Jodie, Tebbutt, Niall C., Carlino, Matteo S., Cebon, Jonathan

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease mā Williams, Benjamin B., Tebbutt, Niall C., Buchert, Michael, Putoczki, Tracy L., Doggett, Karen, Bao, Shisan, Johnstone, Cameron N., Masson, Frederick, Hollande, Frederic, Burgess, Antony W., Scott, Andrew M., Ernst, Matthias, Heath, Joan K.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors mā Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial mā Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis mā Tögel, Lars, Nightingale, Rebecca, Wu, Rui, Chüeh, Anderly C., Al-Obaidi, Sheren, Luk, Ian, Dávalos-Salas, Mercedes, Chionh, Fiona, Murone, Carmel, Buchanan, Daniel D., Chatterton, Zac, Sieber, Oliver M., Arango, Diego, Tebbutt, Niall C., Williams, David, Dhillon, Amardeep S., Mariadason, John M.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer mā Cutsem, Eric Van, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers mā Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel, Scott, Andrew M.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer mā Chionh, Fiona, Gebski, Val, Al-Obaidi, Sheren J., Mooi, Jennifer K., Bruhn, Maressa A., Lee, Chee K., Chüeh, Anderly C., Williams, David S., Weickhardt, Andrew J., Wilson, Kate, Scott, Andrew M., Simes, John, Hardingham, Jennifer E., Price, Timothy J., Mariadason, John M., Tebbutt, Niall C.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

RHOA inactivation enhances Wnt signaling and promotes colorectal cancer mā Rodrigues, Paulo, Macaya, Irati, Bazzocco, Sarah, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Mateo-Lozano, Silvia, Bilić, Josipa, Cartón-García, Fernando, Nieto, Rocio, Suárez-López, Lucia, Afonso, Elsa, Landolfi, Stefania, Hernandez-Losa, Javier, Kobayashi, Kazuto, Cajal, Santiago Ramón y, Tabernero, Josep, Tebbutt, Niall C., Mariadason, John M., Schwartz, Simo, Arango, Diego

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou... mā Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study mā Ohtsu, Atsushi, Ajani, Jaffer A., Bai, Yu-Xian, Bang, Yung-Jue, Chung, Hyun-Cheol, Pan, Hong-Ming, Sahmoud, Tarek, Shen, Lin, Yeh, Kun-Huei, Chin, Keisho, Muro, Kei, Kim, Yeul Hong, Ferry, David, Tebbutt, Niall C., Al-Batran, Salah-Eddin, Smith, Heind, Costantini, Chiara, Rizvi, Syed, Lebwohl, David, Van Cutsem, Eric

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa